Emoxypine

Summary

Emoxypine (CHEMBL3338326) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 137.18 Da · C8H11NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3338326
Name	Emoxypine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	114681
Molecular formula	C8H11NO
Molecular weight	137.18
InChIKey	JPGDYIGSCHWQCC-UHFFFAOYSA-N

SMILES: CCC1=C(C=CC(=N1)C)O

IUPAC name: 2-ethyl-6-methylpyridin-3-ol

Also known as: Emoxipin, Emoxipine, Emoxypin, Epigid, Epygid, Ethylmethylhydroxypyridine, Methylethylpiridinol, EMOXIPIN, Emoxipin hydrochloride, emoxipin, EMOXIPIN HYDROCHLORIDE

Parent form; salt/anhydrous children: CHEMBL6068558

Patent coverage: 199 distinct patent families (470 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 310 (66%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).